NewsAvi Kapoor
Rani Therapeutics Holdings
RANI · NASDAQ
$0.6528+$0.0025 (+0.38%)TodayMarket closed ·
Prev close $0.6503
Latest news
- Press releaseGlobe Newswire
Rani Therapeutics Announces Acceptance into U.S. FDA's Emerging Technology Program (ETP)
- Press releaseGlobe Newswire
Rani Therapeutics Announces Positive Initial Phase 1a Data for RT-114 for the Treatment of Obesity, with Oral Bioavailability Exceeding Matched Subcutaneous Dosing
- Press releaseGlobe Newswire
Rani Therapeutics Appoints Dr. Sara Kenkare-Mitra as Strategic Advisor to Advance Platform and Clinical Strategy
- News
12 Health Care Stocks Moving In Thursday's Pre-Market Session
- News
Earnings Scheduled For March 26, 2026
- Press releaseGlobe Newswire
Rani Therapeutics Initiates Phase 1 Study of RT-114 RaniPill® for the Treatment of Obesity in Collaboration with ProGen
- News
12 Health Care Stocks Moving In Tuesday's After-Market Session
- News
12 Health Care Stocks Moving In Monday's Pre-Market Session
- News
12 Health Care Stocks Moving In Friday's Intraday Session
- News
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- News
12 Health Care Stocks Moving In Tuesday's Intraday Session
- NewsAvi Kapoor
Gold Falls 1%; SLB Posts Better-Than-Expected Q3 Earnings
- NewsAvi Kapoor
Dow Gains Over 100 Points; American Express Increases 2025 Forecast
- Press releaseGlobe Newswire
Rani Therapeutics Announces up to $1.085 Billion Collaboration with Chugai Pharmaceutical Co. for Multiple High-Value Therapeutics Including Rare Disease and Immunology Programs and Announces Concurrent Oversubscribed $60.3 Million Financing
- News
12 Health Care Stocks Moving In Wednesday's After-Market Session
- News
12 Health Care Stocks Moving In Tuesday's Intraday Session
- NewsAvi Kapoor
Nasdaq Gains Over 100 Points; Wells Fargo Earnings Top Views
- NewsAvi Kapoor
Dow Falls Over 100 Points; JPMorgan Posts Upbeat Earnings
- News
Watching Rani Therapeutics; Zacks Small-Cap Research Gives Stock $12 Price Valuation
- Press releaseGlobe Newswire
Rani Therapeutics Announces Preclinical Data Demonstrating Bioequivalence of RT-114, a GLP-1/GLP-2 Dual Agonist (PG-102) Delivered Orally via the RaniPill® Capsule, to Subcutaneously Administered PG-102
- News
12 Health Care Stocks Moving In Thursday's Pre-Market Session
- NewsRishabh Mishra
US Stocks Likely To Open Higher Ahead Of Amazon's Earnings: 'Buy The Dip' Mentality Remains Prevalent, Says Analyst
- News
Watching Rani Therapeutics; Zacks Small-Cap Research Gives Stock $12 Price Valuation
- NewsHenry Khederian
Why Rani Therapeutics Shares Are Down 23% Today
- NewsAvi Kapoor
Why Longboard Pharmaceuticals Shares Are Trading Higher By Around 47%; Here Are 20 Stocks Moving Premarket
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.